Context Therapeutics Inc. (CNTX) News
Track canonical SquawkNews coverage tagged to CNTX, Context Therapeutics Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
CNTX - Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
CNTX - Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
EQUITY | Sep 09, 2026, 11:30 AM UTC
L
Why SiTime Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
Shares of SiTime Corp (NASDAQ: SITM ) rose sharply in pre-market trading after the company reported better-than-expected second- quarter financial results. SiTime reported quarterly earnings of $2.34 per share which beat
EARNINGS | Aug 06, 2026, 08:55 AM UTC
M
Context Therapeutics Reports Q2 Progress
Context Therapeutics reports Q2 operating progress
EQUITY | Aug 05, 2026, 08:14 PM UTC